Author

Fernando Jose Magro Dias 1

1 Gastrenterology,Centro Hospitalar São João,Porto,Portugal

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations

Paolo Gionchetti, Axel Dignass, Sllvio Danese, Fernando Jose Magro Dias, Gerhard Rogler, Peter L Lakatos, Michel Adamina, Alessandro Ardizzone, Christianne Johanna Buskens, Shaji Sebastian, Silvio Laureti, Gianluca M Sampietro, Boris Vucelic, C. Janneke van der Woude, Manuel Barreiro de Acosta, Christian Maaser, Francisco P

ACCURACY OF CALPROTECTIN AND NGAL IN EVALUATING HISTOLOGICAL SUB-CLINICAL INFLAMMATION IN ULCERATIVE COLITIS (ACERTIVE- STUDY)

Fernando Jose Magro Dias, Susana Lopes, Rosa Coelho, José Berkeley Cotter, Tania Meira, Ana Patrícia Andrade, Helena T. Sousa, Marta Salgado, Paulo Caldeira, Claudia Camila-Dias, Paula Borralho, Karel Geboes, Joana Afonso, Fatima Carneiro

ACCURACY OF CALPROTECTIN AND NGAL IN EVALUATING HISTOLOGICAL SUB-CLINICAL INFLAMMATION IN ULCERATIVE COLITIS (ACERTIVE- STUDY)

Fernando Jose Magro Dias

AN OPEN LABEL PROSPECTIVE STUDY OF THESOLUBLE SERUM MARKER ST2 (IL-33 RECEPTOR) IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS TREATED WITH GOLIMUMAB: CLINICAL, ENDOSCOPIC AND HISTOLOGICAL RESULTS OF THE EVOLUTION STUDY

Fernando Jose Magro Dias, Susana Lopes, Marco Silva, Francisco Portela, Diogo Branquinho, Luis Correia, Samuel Fernandes, Marilia Lopes Cravo, Paulo Caldeira, Maria Helena Tavares Sousa, Marta Patita, Isabelle Cremers, Joana Afonso, Isabel Redondo, Patricia Machado, George Philip, Joanne Lopes, Fatima Carneiro

ANTI-TNF INDUCED PSORIASIS IN INFLAMMATORY BOWEL DISEASE: A 10-YEAR EXPERIENCE

Ana Patrícia Andrade, Susana Lopes, Rui Gaspar, Amadeu CR Nunes, Fernando Jose Magro Dias, Sofia Magina, Guilherme Macedo

ANTI-TNF THERAPY AND DISEASE PHENOTYPE: DETERMINANTS OF RISK OF RADIATION EXPOSURE IN CROHN'S DISEASE

Rosa Coelho, Luis Guimarães, Susana Lopes, Fernando Jose Magro Dias, Guilherme Macedo

ASSESSMENT OF HISTOLOGICAL REMISSION IN PATIENTS TREATED WITH FILGOTINIB BY DIFFERENT SCORES AND CONCORDANCE WITH ENDOSCOPIC AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES: POST HOC ANALYSIS FROM THE SELECTION STUDY

Fernando Magro

ASSESSMENT OF HISTOLOGICAL REMISSION IN PATIENTS TREATED WITH FILGOTINIB BY DIFFERENT SCORES AND CONCORDANCE WITH ENDOSCOPIC AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES: POST HOC ANALYSIS FROM THE SELECTION STUDY

Fernando Magro, Laurent Peyrin-Biroulet, Gerhard Rogler, Alessandra Oortwijn, Haridarshan Patel, Angela de Haas, Eva Santermans, Haoyao Ruan, Louis Dron, Brian G. Feagan

ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Fernando Magro, Gert De Hertogh, Marijana Protic, Lai Shan Chan, Paul Pollack, Brian G. Feagan, Noam Harpaz, Rish Pai, Walter Reinisch

ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Fernando Magro

Item 1 - 10 / 85
1
2 3 4 5 6 7 8 9